GNI Group
GNI Group Ltd is a Japanese biopharmaceutical company discovering, developing, and commercializing therapeutics for fibrotic diseases and organ failure across East Asia and the United States. The company commercializes Etuary (pirfenidone), a small molecule anti-fibrotic prescription drug for idiopathic pulmonary fibrosis (IPF) and liver fibrosis, alongside developing medical devices via Gyre Therapeutics and Cullgen protein degradation platforms. Revenue is generated from commercial drug product sales of Etuary, clinical research milestone payments, and medical device product sales across China and the US. Core end markets serve pulmonology medical departments, hepatology hospital clinics, prescription IPF patients, and medical device distributors in China, Japan, and North America. GNI Group holds a market-leading position in China for pulmonary fibrosis anti-fibrotic prescription therapeutics. The corporation is headquartered in Tokyo, Japan, and its common stock trades on the Tokyo Stock Exchange Growth market.
3 of the funds FundTelligence covers report a position in GNI Group.
- Legal name
- GNI Group Ltd
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 3
Funds holding GNI Group
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)